Autopsy report · NCT05820152

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations

“Due to the sponsor circumstances and external reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 10 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Neurophth Therapeutics Inc

Sponsor type

University, hospital or other

Conditions

Leber Hereditary Optic Neuropathy (LHON)

Interventions

NFS-02 Injection

Participants

11

Sites

4

Countries

China, United States

Trials that died the same way

• BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers
  “Due to Sponsor's financial reasons” (93% match in meaning)
• Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS
  “Due to sponsor decision” (87% match in meaning)
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
  “Due to sponsor request” (82% match in meaning)
• A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
  “Not due to safety reasons (sponsor decision).” (79% match in meaning)
• Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation
  “Sponsor business reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.